This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2007 Mar;33(3):396-9.

doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.

Increasing evidence that the risks of rhAPC may outweigh its benefits

Peter Q Eichacker, Charles Natanson

PMID: 17325833
DOI: 10.1007/s00134-007-0556-8

Editorial

Increasing evidence that the risks of rhAPC may outweigh its benefits

Peter Q Eichacker et al. Intensive Care Med. 2007 Mar.

. 2007 Mar;33(3):396-9.

doi: 10.1007/s00134-007-0556-8. Epub 2007 Feb 15.

Authors

Peter Q Eichacker, Charles Natanson

PMID: 17325833
DOI: 10.1007/s00134-007-0556-8

No abstract available

PubMed Disclaimer

Comment in

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions.
Williams MD, Macias W, Rustige J. Williams MD, et al. Intensive Care Med. 2007 Aug;33(8):1487-8; author reply 1489-91. doi: 10.1007/s00134-007-0709-9. Epub 2007 Jun 12. Intensive Care Med. 2007. PMID: 17563878 No abstract available.
Is there increasing evidence that the risks of rhAPC may outweigh its benefits?
Plataki M, Vaporidi K, Georgopoulos D. Plataki M, et al. Intensive Care Med. 2007 Aug;33(8):1485-6; author reply 1489. doi: 10.1007/s00134-007-0707-y. Epub 2007 Jun 12. Intensive Care Med. 2007. PMID: 17563880 No abstract available.

Comment on

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D. Bertolini G, et al. Intensive Care Med. 2007 Mar;33(3):426-34. doi: 10.1007/s00134-007-0554-x. Epub 2007 Feb 15. Intensive Care Med. 2007. PMID: 17325836
Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.
Kanji S, Perreault MM, Chant C, Williamson D, Burry L. Kanji S, et al. Intensive Care Med. 2007 Mar;33(3):517-23. doi: 10.1007/s00134-007-0555-9. Epub 2007 Feb 15. Intensive Care Med. 2007. PMID: 17325837

Similar articles

Risks and benefits of activated protein C treatment for severe sepsis.
Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Warren HS, et al. N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574. N Engl J Med. 2002. PMID: 12324562 No abstract available.
Adverse events and clinical outcome associated with drotrecogin alfa-activated: a single-center experience of 498 patients over 8 years.
Boyle A, McKenzie C, Yassin S, McLuckie A, Wyncoll D. Boyle A, et al. J Crit Care. 2012 Jun;27(3):320.e7-12. doi: 10.1016/j.jcrc.2011.07.004. Epub 2011 Dec 14. J Crit Care. 2012. PMID: 22172792
Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
Kalil AC, LaRosa SP. Kalil AC, et al. Lancet Infect Dis. 2012 Sep;12(9):678-86. doi: 10.1016/S1473-3099(12)70157-3. Epub 2012 Jul 17. Lancet Infect Dis. 2012. PMID: 22809883
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].
Heslet L, Nielsen JD, Schierbeck J, Andersen JS. Heslet L, et al. Ugeskr Laeger. 2004 Mar 8;166(11):997-1002. Ugeskr Laeger. 2004. PMID: 15049234 Review. Danish. No abstract available.
Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
Laterre PF, Wittebole X. Laterre PF, et al. Crit Care. 2003 Dec;7(6):445-50. doi: 10.1186/cc2342. Epub 2003 Jun 30. Crit Care. 2003. PMID: 14624684 Free PMC article. Review.

See all similar articles

Cited by

An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.
Kumar A. Kumar A. Virulence. 2014 Jan 1;5(1):80-97. doi: 10.4161/viru.26913. Epub 2013 Nov 1. Virulence. 2014. PMID: 24184742 Free PMC article. Review.
Early antimicrobial therapy in severe sepsis and septic shock.
Kumar A. Kumar A. Curr Infect Dis Rep. 2010 Sep;12(5):336-44. doi: 10.1007/s11908-010-0128-x. Curr Infect Dis Rep. 2010. PMID: 21308515
How the context of reception affects the meaning of RCT evidence.
Carmel S. Carmel S. Health (London). 2024 Mar;28(2):253-271. doi: 10.1177/13634593221134011. Epub 2022 Nov 5. Health (London). 2024. PMID: 36341702 Free PMC article. Clinical Trial.
Once is not enough: clinical trials in sepsis.
Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Sweeney DA, et al. Intensive Care Med. 2008 Nov;34(11):1955-60. doi: 10.1007/s00134-008-1274-6. Epub 2008 Oct 7. Intensive Care Med. 2008. PMID: 18839140 No abstract available.
Editors' comments on a new trial of activated protein C for persistent septic shock.
Mancebo J, Antonelli M. Mancebo J, et al. Intensive Care Med. 2008 Nov;34(11):1948-9. doi: 10.1007/s00134-008-1303-5. Epub 2008 Oct 7. Intensive Care Med. 2008. PMID: 18839138 No abstract available.

See all "Cited by" articles

References

1. N Engl J Med. 2006 Jan 26;354(4):413-5 - PubMed
1. N Engl J Med. 2006 Jan 26;354(4):329-31 - PubMed
1. Crit Care Med. 2005 Oct;33(10 ):2426-8 - PubMed
1. Intensive Care Med. 2007 Mar;33(3):517-23 - PubMed
1. N Engl J Med. 2001 Mar 8;344(10 ):699-709 - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information